ReviewMicrobial ecology2021
Paediatric Inflammatory Bowel Disease and its Relationship with the Microbiome.
Review in Microbial ecology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review.Frontiers in pharmacology · 2026Pooled it
- Saudi consensus guidance for the diagnosis and management of inflammatory bowel disease in children and adolescents.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Guideline
- Stool microbial composition is associated with recent and future diarrhea and fever events in breastfed Danish infants.mSystems · 2026Observational
- Post-Surgical Gut Microbiota Alterations in Pediatric Patients with Intestinal Disorders.Journal of clinical medicine · 2026Review
- Microbial signature of pediatric Crohn's disease: Differentiation from functional gastrointestinal disorders and relationship with increased disease activity.Physiological reports · 2026Article
- Fecal microbial and metabolic signatures in children with very early onset inflammatory bowel disease.NPJ biofilms and microbiomes · 2025Article
- Nutritional Approach in Pediatric Patients with Inflammatory Bowel Disease: Treatment, Risk and Challenges.Nutrients · 2025Review
- Combining mucosal microbiome and host multi-omics data shows prognostic potential in paediatric ulcerative colitis.Nature communications · 2025Article
- Integrated multi-omics of feces, plasma and urine can describe and differentiate pediatric active Crohn's Disease from remission.Communications medicine · 2025Article
- Alterations of gut microbiota and metabolites in children with Crohn's disease and their correlation with disease activity.Translational pediatrics · 2025Article
- Anti-Tumor Necrosis Factor-α Use in Pediatric Inflammatory Bowel Disease-Reports from a Romanian Center.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Evaluation of microbiome composition combined with serum untargeted metabolomic profiling in newly diagnosed children with inflammatory bowel disease.Archives of medical science : AMS · 2025Article
- The early-life gut microbiome in common pediatric diseases: roles and therapeutic implications.Frontiers in nutrition · 2025Review
- Review
- Role ofWorld journal of gastroenterology · 2024Review
- Gut-microbiota-based ensemble model predicts prognosis of pediatric inflammatory bowel disease.iScience · 2024Article
- Neutrophil Extracellular Traps in Pediatric Inflammatory Bowel Disease: A Potential Role in Ulcerative Colitis.International journal of molecular sciences · 2024Article
- Necrotizing Enterocolitis and Neurodevelopmental Impairments: Microbiome, Gut, and Brain Entanglements.Biomolecules · 2024Review
- Bifidogenic Effect of Human Milk Oligosaccharides on Pediatric IBD Fecal Microbiota.Microorganisms · 2024Article
- Studies of the Impact of the Bifidobacterium Species on Inducible Nitric Oxide Synthase Expression and Nitric Oxide Production in Murine Macrophages of the BMDM Cell Line.Probiotics and antimicrobial proteins · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Paediatric inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the digestive tract, comprising of Crohn's disease (CD), ulcerative colitis (UC), and, where classification is undetermined, inflammatory bowel disease unclassified (IBDU). Paediatric IBD incidence is increasing globally, with prevalence highest in the developed world. Though no specific causative agent has been identified for paediatric IBD, it is believed that a number of factors may contribute to the development of the disease, including genetics and the environment. Another potential component in the development of IBD is the microbiota in the digestive tract, particularly the gut. While the exact role that the microbiome plays in IBD is unclear, many studies acknowledge the complex relationship between the gut bacteria and pathogenesis of IBD. In this review, we look at the increasing number of studies investigating the role the microbiome and other biomes play in paediatric patients with IBD, particularly changes associated with IBD, varying disease states, and therapeutics. The paediatric IBD microbiome is significantly different to that of healthy children, with decreased diversity and differences in bacterial composition (such as a decrease in Firmicutes). Changes in the microbiome relating to various treatments of IBD and disease severity have also been observed in multiple studies. Changes in diversity and composition may also extend to other biomes in paediatric IBD, such as the virome and the mycobiome. Research into biome differences in IBD paediatric patients may help progress our understanding of the aetiology of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.